Under the UK government’s expanded subscription-style model for antimicrobials, successful companies could be awarded payments of up to £20m ($25m) for novel antibiotics based on their value to the National Health Service (NHS) – but only those that can demonstrate compliance with responsible manufacturing standards will be considered.
Key Takeaways
-
Applicants to the UK’s subscription payment model for antimicrobials must be BSI Kitemark certified to demonstrate their commitment to minimizing AMR.
Companies looking to apply to the scheme, which has been likened to Netflix due to the subscription-style payments it makes,...








